Analysis: Bristol-Myers Squibb (BMY) Stock Could Be 12.2% Undervalued

An analysis by Simply Wall St suggests that Bristol-Myers Squibb (BMY) stock may be undervalued by 12.2%, with shares closing at US$55.28. This comes amid a mixed performance: the stock fell 3.54% over the past 30 days and 4.87% over 90 days, but delivered a 23.92% total shareholder return over the past year.

Recommendation Change

The report does not provide an explicit buy or sell recommendation but highlights the potential undervaluation based on fundamental factors.

Analyst Rationale

Analysts at Simply Wall St believe the stock is 12.2% undervalued, supported by hopes for the company's pipeline and margin improvements. However, the mixed growth profile across revenue, earnings, and long-term returns creates uncertainty.

Context

The stock has underperformed in the short term, declining 3.54% in the last month and 4.87% over three months. Long-term holders, however, have seen a 23.92% total return over the past year, indicating cautious optimism.

What We Conclude

While the analysis points to a potential investment opportunity, the mixed performance warrants careful assessment of risks and potential returns before making any investment decision.